More about

Drug-Eluting Stent

News
May 19, 2021
1 min read
Save

I-LOVE-IT-2

I-LOVE-IT-2

Biodegradable polymer sirolimus-eluting stent (Tivoli, Essen) vs. durable polymer SES (Firebird2, Microport) in patients with CAD.

News
May 15, 2021
2 min read
Save

TWILIGHT: Benefit of ticagrelor monotherapy after PCI similar in men, women

TWILIGHT: Benefit of ticagrelor monotherapy after PCI similar in men, women

Among patients who underwent PCI with a drug-eluting stent, switching from dual antiplatelet therapy to ticagrelor monotherapy at 3 months was similarly beneficial in men and women, according to new data from the TWILIGHT trial.

News
April 20, 2021
1 min read
Save

BIOSTEMI

BIOSTEMI

SES with biodegradable polymer (Orsiro, Biotronik) vs. EES with durable polymer (Xience Xpedition/Alpine, Abbott Vascular) for PCI in patients with STEMI.

News
March 18, 2021
2 min read
Save

BIOSTEMI: Biodegradable SES remains superior to durable EES at 2 years

BIOSTEMI: Biodegradable SES remains superior to durable EES at 2 years

A biodegradable polymer sirolimus-eluting stent remained superior to a durable polymer everolimus-eluting stent at 2 years, researchers reported.

News
February 18, 2021
1 min read
Save

PIONEER III

PIONEER III

Novel healing-targeted drug-eluting stent (HT-DES; BuMA Supreme, Sinomed) vs. durable polymer everolimus-eluting stents for PCI.

News
January 25, 2021
1 min read
Save

FDA approves new DES system for large, proximal vessels

FDA approves new DES system for large, proximal vessels

Boston Scientific announced it received FDA approval for its drug-eluting stent system designed to treat large, proximal vessels.

News
December 23, 2020
2 min read
Save

DAPT duration does not impact outcomes after PCI with SES

DAPT duration does not impact outcomes after PCI with SES

Among patients who underwent PCI with a sirolimus-eluting stent, short-term and long-term dual antiplatelet therapy conferred similar rates of target vessel failure, researchers reported.

News
December 09, 2020
2 min read
Save

No mortality signal in trial paused due to paclitaxel-coated device concerns

No mortality signal in trial paused due to paclitaxel-coated device concerns

An interim analysis of the SWEDEPAD trial, which was paused after a meta-analysis detected a mortality hazard associated with paclitaxel-coated devices, found no death risk from the devices in patients with peripheral artery disease.

News
November 21, 2020
1 min read
Save

Top news from VIVA: Drug-coated devices, treatments for PAD and more

Top news from VIVA: Drug-coated devices, treatments for PAD and more

Healio and Cardiology Today have aggregated the most-read news from the virtual VIVA 20.

News
November 19, 2020
1 min read
Save

COBRA-REDUCE

COBRA-REDUCE

Outcomes with 14 days of dual antiplatelet therapy after PCI with a nanocoated stent (Cobra PzF, CeloNova Biosciences) compared with 3- to 6-month DAPT after PCI with a drug-eluting stent.

View more